Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 5:15 PM ET
Company Participants
Leonard Schleifer – Board Co-Chair, Co-Founder, President and CEO
George Yancopoulos – Co-Founder, Board Co-Chair, President & CSO
Conference Call Participants
Chris Schott – JPMorgan
Good afternoon, everybody. I’m Chris Schott from J.P. Morgan, and it’s my pleasure to be introducing Regeneron today. From the company, we have Regeneron’s co-Founders and co-Chairs, President and CEO, Len Schleifer, as well as President and CSO, George Yancopoulos. With a lot of updates on the core business and actually particularly the pipeline, very much looking forward to the presentation today.
So we’re going to have, Len and George make a presentation, and then we’ll have a little fireside chat after that. So with that, over to Len.
Leonard Schleifer
Thank you. Thank you, Chris, for that very detailed and warm introduction. Let’s see if I can get the slides going here. So this is our forward-looking statement slide, and while you’re looking at that, I thought it might make sense for me to make a few backward looking statements.
I, as perhaps the longest serving CEO in the biotechnology industry and along with George, part of the longest serving, management team in the biotechnology industry, I’ve been speaking in this conference for more than three decades. And while many things have changed, there have been different themes. Is it a platform? Is it small molecules? Is it RNA? Is it vaccines? Is it biologics? Or that rotates and change. There’s one constant and the constant is investors always want to know what is that one thing that your company has that should make us want to invest.
And in the early days of Regeneron, I answered that question in sort of obtuse way. I said, well it’s
Credit: Source link
